Alejandra Riera Gonzalez, MD
Endocrinology, Diabetes & Metabolism · Marrero, LANPI 1306258884
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Pfizer at 41.9% of the total. 2025 is the largest year on record at $2,533, more than ten times the $211 reported in 2019.
Across 216 payments — averaging $33.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- Novo Nordisk$1K
- Lilly USA, LLC$434
- Amgen$258
- Corcept Therapeutics$247
- Abbott$217
- plus $2K from 30 others
What the payments were for
- Consulting fees$2,00027%
- Travel & lodging$94613%
- Food & beverage$4,39360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer(2 entities) | 11 | $3,077 |
| Novo Nordisk | 60 | $1,216 |
| Lilly USA, LLC | 18 | $434 |
| Amgen | 16 | $258 |
| Corcept Therapeutics | 7 | $247 |
| Abbott | 10 | $217 |
| Sanofi-aventis U.S. LLC | 9 | $176 |
| Xeris Pharmaceuticals, Inc. | 8 | $171 |
| AstraZeneca(2 entities) | 8 | $168 |
| Dexcom, Inc. | 4 | $167 |
| Bayer | 9 | $163 |
| Boehringer Ingelheim | 8 | $161 |
| Tandem Diabetes Care, Inc. | 3 | $97 |
| Ascensia Diabetes Care US Inc. | 5 | $81 |
| Amneal Pharmaceuticals LLC | 5 | $76 |
| Recordati_rare_diseases_inc. | 4 | $74 |
| Merck | 4 | $73 |
| Esperion Therapeutics, Inc. | 3 | $49 |
| AbbVie | 2 | $48 |
| IBSA Pharma Inc. | 3 | $47 |
| Theratechnologies Inc. | 2 | $38 |
| Ascendis Pharma Endocrinology Inc | 2 | $36 |
| Valeritas, Inc. | 2 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| Almatica Pharma LLC | 1 | $23 |
| Antares Pharma, Inc. | 1 | $21 |
| Averitas Pharma Inc. | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| BETA Bionics, Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Medtronic | 1 | $17 |
| Mannkind Corporation | 1 | $16 |
| Amphastar Pharmaceuticals, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| GSK | 1 | $12 |
| Cequr Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$2,850
- Ozempic$244
- Korlym$124
- DEXCOM G7 GSS (161)$111
How this compares
$7,339 in reported general payments places this provider in the 65th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 175 | $298,468 |
| MounjaroTirzepatide | 222 | $258,007 |
| JardianceEmpagliflozin | 108 | $136,409 |
| ForteoTeriparatide | 12 | $48,680 |
| JanuviaSitagliptin Phosphate | 36 | $39,291 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $32,365 |
| TrulicityDulaglutide | 17 | $28,236 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $16,621 |
| KerendiaFinerenone | 14 | $13,131 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $11,026 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $8,960 |
| XyostedTestosterone Enanthate | 11 | $6,684 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $5,170 |
| Novolog FlexpenInsulin Aspart | 17 | $4,256 |
| LevoxylLevothyroxine Sodium | 85 | $4,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Forteo, Trulicity | $434 | $334,924251 claims |
| Novo NordiskOzempic | $1,216 | $298,468175 claims |
| Boehringer IngelheimJardiance | $161 | $136,409108 claims |
| MerckJanuvia | $73 | $39,29136 claims |
| BayerKerendia | $163 | $13,13114 claims |
| Antares Pharma, Inc.Xyosted | $21 | $6,68411 claims |
| PfizerLevoxyl | $3,077 | $4,04685 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $76 | $2,573180 claims |
| AbbVieSynthroid | $48 | $1,17812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Marrero
- Marideli ScanlanMarrero$444K
- Tilak MallikMarrero$51K
- Sarah KeslerMarrero$5K
- Amy VarugheseMarrero$3K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Justin FontenotLafayette$397K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.